Pharma firms lean on US trademark law to halt weight loss drug counterfeits

Drug companies are increasingly turning to the Lanham Act in the US to stop the distribution of GLP-1 weight loss medications by compounding pharmacies. Industry leaders say compounded drugs sold as...

Already a subscriber? Click here to view full article